The company raised total-revenue guidance to a range of $3.875 billion to $3.925 billion and raised non-GAAP earnings-per-share guidance to $4.90 to $5.10. BioMarin raised its financial outlook after second-quarter revenue approached $1 billion, lifting 2025 revenue guidance to $3.875 billion–$3.925 billion and non-GAAP EPS guidance to $4.90–$5.10. For Galafold, BioMarin sees an opportunity to improve diagnosis of Fabry disease, which Mueller said remains significantly underdiagnosed. The company also raised revenue guidance for VOXZOGO to at least $1 billion after what Mueller described as strong first-half performance. The article "BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth" was originally published by MarketBeat.